AGL antibody (C-Term)

Catalog No. ABIN2839247

The Rabbit Polyclonal anti-AGL antibody has been validated for WB and IF. It is suitable to detect AGL in samples from Human. There are 6+ publications available.

Quick Overview for AGL antibody (C-Term) (ABIN2839247)

Target: AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This AGL antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF)

Clone: RB4978

Product Details anti-AGL Antibody

Binding Specificity: AA 1479-1510, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This AGL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1479-1510 amino acids from the C-terminal region of human AGL.

Isotype: Ig Fraction

Application Details

Application Notes: IF: 1:10~50. IF: 1:10~50. WB: 1:1000. WB: 1:8000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-AGL antibody (ABIN2839247)

Guin, Ru, Agarwal, Ritterson Lew, Owens, Comi, Theodorescu: "Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis." in: Clinical cancer research : an official journal of the American Association for Cancer Research, (2015) (PubMed).

Liu, Zeng, Ma, Baba, Zheng, Liu, Wang: "Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase." in: Molecular neurobiology, Vol. 49, Issue 2, pp. 645-57, (2014) (PubMed).

Zhu, Shen, Zhu, Coorey, Nguyen, Barthelmes, Gillies: "Anti-retinal antibodies in patients with macular telangiectasia type 2." in: Investigative ophthalmology & visual science, Vol. 54, Issue 8, pp. 5675-83, (2013) (PubMed).

DePaoli-Roach, Tagliabracci, Segvich, Meyer, Irimia, Roach: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin." in: The Journal of biological chemistry, Vol. 285, Issue 33, pp. 25372-81, (2010) (PubMed).

Parker, Kong, Walsh, Salajegheh, Moghadaszadeh, Amato, Nazareno, Lin, Krastins, Sarracino, Beggs, Pinkus, Greenberg: "Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis." in: Muscle & nerve, Vol. 39, Issue 6, pp. 739-53, (2009) (PubMed).

Cheng, Zhang, Gentry, Worby, Dixon, Saltiel: "A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease." in: Genes & development, Vol. 21, Issue 19, pp. 2399-409, (2007) (PubMed).

Target Details for AGL

Target: AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))

Alternative Name: AGL

Background: AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.

Molecular Weight: 174764

Gene ID: 178

NCBI Accession: NP_000019, NP_000633, NP_000634, NP_000635, NP_000636, NP_000637

UniProt: P35573

Pathways: Cellular Glucan Metabolic Process